Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem Melphalan + Bortezomib in Multiple Myeloma
NCT01241708Phase 3Completed
- Sponsor
- Hackensack Meridian Health
- Start
- Apr 2010
- Primary completion
- Jul 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by Hackensack Meridian Health. Started Apr 2010; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01241708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241708.